FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2932649662> ?p ?o ?g. }

• W2932649662 endingPage "395" @default.
• W2932649662 startingPage "377" @default.
• W2932649662 abstract "PurposeTo assess how often non-infectious anterior scleritis remits and identify predictive factors.MethodsOur retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models.ResultsDuring 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within ≤90 days was associated with more remission incidence.ConclusionsOur results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed. To assess how often non-infectious anterior scleritis remits and identify predictive factors. Our retrospective cohort study at four ocular inflammation subspecialty centers collected data for each affected eye/patient at every visit from center inception (1978, 1978, 1984, 2005) until 2010. Remission was defined as inactivity of disease off all suppressive medications at all visits spanning at least three consecutive months or at all visits up to the last visit (to avoid censoring patients stopping follow-up after remission). Factors potentially predictive of remission were assessed using Cox regression models. During 1,906 years' aggregate follow-up of 832 affected eyes, remission occurred in 214 (170 of 584 patients). Median time-to-remission of scleritis = 7.8 years (95% confidence interval [CI]: 5.7, 9.5). More remissions occurred earlier than later during follow-up. Factors predictive of less scleritis remission included scleritis bilaterality (adjusted hazard ratio [aHR] = 0.46, 95% CI: 0.32-0.65); and diagnosis with any systemic inflammatory disease (aHR = 0.36, 95% CI: 0.23-0.58), or specifically with Rheumatoid Arthritis (aHR = 0.22), or Granulomatosis with Polyangiitis (aHR = 0.08). Statin treatment (aHR = 1.53, 95% CI: 1.03-2.26) within ≤90 days was associated with more remission incidence. Our results suggest scleritis remission occurs more slowly in anterior scleritis than in newly diagnosed anterior uveitis or chronic anterior uveitis, suggesting that attempts at tapering suppressive medications is warranted after long intervals of suppression. Remission is less frequently achieved when systemic inflammatory diseases are present. Confirmatory studies of whether adjunctive statin treatment truly can enhance scleritis remission (as suggested here) are needed." @default.
• W2932649662 created "2019-04-11" @default.
• W2932649662 creator A5006274430 @default.
• W2932649662 creator A5012888712 @default.
• W2932649662 creator A5012947410 @default.
• W2932649662 creator A5013003481 @default.
• W2932649662 creator A5016920591 @default.
• W2932649662 creator A5027427092 @default.
• W2932649662 creator A5027692434 @default.
• W2932649662 creator A5031802215 @default.
• W2932649662 creator A5041124754 @default.
• W2932649662 creator A5043549024 @default.
• W2932649662 creator A5050030287 @default.
• W2932649662 creator A5051180440 @default.
• W2932649662 creator A5062196360 @default.
• W2932649662 creator A5081277381 @default.
• W2932649662 creator A5081857642 @default.
• W2932649662 creator A5082563606 @default.
• W2932649662 date "2021-03-01" @default.
• W2932649662 modified "2023-09-24" @default.
• W2932649662 title "Remission of Non-Infectious Anterior Scleritis: Incidence and Predictive Factors" @default.
• W2932649662 cites W1561583923 @default.
• W2932649662 cites W1965835206 @default.
• W2932649662 cites W1974162532 @default.
• W2932649662 cites W1984922955 @default.
• W2932649662 cites W1991488419 @default.
• W2932649662 cites W2003095957 @default.
• W2932649662 cites W2006142366 @default.
• W2932649662 cites W2009913923 @default.
• W2932649662 cites W2011826792 @default.
• W2932649662 cites W2012658469 @default.
• W2932649662 cites W2015410642 @default.
• W2932649662 cites W2024153528 @default.
• W2932649662 cites W2026923232 @default.
• W2932649662 cites W2027090790 @default.
• W2932649662 cites W2039266991 @default.
• W2932649662 cites W2044457654 @default.
• W2932649662 cites W2045952946 @default.
• W2932649662 cites W2046411916 @default.
• W2932649662 cites W2054542926 @default.
• W2932649662 cites W2054695106 @default.
• W2932649662 cites W2058118563 @default.
• W2932649662 cites W2058451179 @default.
• W2932649662 cites W2059080840 @default.
• W2932649662 cites W2060721487 @default.
• W2932649662 cites W2061198727 @default.
• W2932649662 cites W2065666568 @default.
• W2932649662 cites W2067260112 @default.
• W2932649662 cites W2074159405 @default.
• W2932649662 cites W2075820715 @default.
• W2932649662 cites W2077096469 @default.
• W2932649662 cites W2079706280 @default.
• W2932649662 cites W2090900744 @default.
• W2932649662 cites W2092817423 @default.
• W2932649662 cites W2095730453 @default.
• W2932649662 cites W2100631748 @default.
• W2932649662 cites W2104753416 @default.
• W2932649662 cites W2106608674 @default.
• W2932649662 cites W2112901522 @default.
• W2932649662 cites W2116724316 @default.
• W2932649662 cites W2116778676 @default.
• W2932649662 cites W2129207686 @default.
• W2932649662 cites W2130504616 @default.
• W2932649662 cites W2131882149 @default.
• W2932649662 cites W2139499737 @default.
• W2932649662 cites W2142248480 @default.
• W2932649662 cites W2143480295 @default.
• W2932649662 cites W2149145923 @default.
• W2932649662 cites W2150714926 @default.
• W2932649662 cites W2156308487 @default.
• W2932649662 cites W2157348613 @default.
• W2932649662 cites W2163222700 @default.
• W2932649662 cites W2168911347 @default.
• W2932649662 cites W2169539768 @default.
• W2932649662 cites W2170282519 @default.
• W2932649662 cites W2189826705 @default.
• W2932649662 cites W2228836973 @default.
• W2932649662 cites W2326254244 @default.
• W2932649662 cites W2521428759 @default.
• W2932649662 cites W2534441626 @default.
• W2932649662 cites W2566189108 @default.
• W2932649662 cites W2605864558 @default.
• W2932649662 cites W2610629369 @default.
• W2932649662 cites W2742987084 @default.
• W2932649662 cites W2802424244 @default.
• W2932649662 cites W4235790631 @default.
• W2932649662 cites W764788035 @default.
• W2932649662 cites W83163415 @default.
• W2932649662 cites W2759495360 @default.
• W2932649662 doi "https://doi.org/10.1016/j.ajo.2019.03.024" @default.
• W2932649662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30951689" @default.
• W2932649662 hasPublicationYear "2021" @default.
• W2932649662 type Work @default.
• W2932649662 sameAs 2932649662 @default.
• W2932649662 citedByCount "11" @default.
• W2932649662 countsByYear W29326496622020 @default.
• W2932649662 countsByYear W29326496622021 @default.
• W2932649662 countsByYear W29326496622022 @default.

• next